" class="no-js "lang="en-US"> Sirnaomics - Medtech Alert
Thursday, September 18, 2025
Sirnaomics | Pharmtech Focus

Sirnaomics

About Sirnaomics

Sirnaomics

Sirnaomics is an RNA therapeutics biopharmaceutical company with product candidates in preclinical and clinical stages that focuses on the discovery and development of innovative drugs for indications with medical needs and large market opportunities. Sirnaomics is the first clinical-stage RNA therapeutics company to have a strong presence in both China and the United States, and also the first company to achieve positive Phase IIa clinical outcomes in oncology for an RNAi therapeutic for its core product, STP705.

Related Story

Sirnaomics Develops Peptide Docking Vehicle (PDoV(TM)) Designed for an Enhanced GalNAc Delivery Platform for Novel siRNA Therapeutics

August 16 2022

Sirnaomics Ltd. (the “Company” or “Sirnaomics“, stock code: 2257.HK), a leading biopharmaceutical company in discovery and development […]